Functional Diversity of DNA Methyltransferase Inhibitors in Human Cancer Cell Lines

A team of German researchers from the Deutsch Krebsforschungszentrum (German Cancer Research Center) has made a significant breakthrough in the field of cancer therapy. The study, published in Cancer Research, has revealed that cancer cell DNA methyltransferase inhibitors display functional diversity. This discovery has the potential to revolutionize cancer treatment, as it provides valuable insights into the developmental potential of individual drugs. The researchers have identified six DNA methyltransferase inhibitors and tested their effects on human cancer cell lines, revealing substantial diversity in their molecular activities.

Key Takeaways:

• The study identified six DNA methyltransferase inhibitors: 5-azacytidine (5-aza-CR), 5-aza-2'-deoxycytidine (5-aza-CdR), zebularine, procaine, (-)-epigallocatechin-3-gallate (EGCG), and RG108.
• 5-aza-CR, 5-aza-CdR, zebularine, and EGCG were found to exhibit significant cytotoxicity in human cancer cell lines.
• 5-aza-CdR and EGCG were also found to be genotoxic, as evidenced by the induction of micronuclei.
• 5-aza-CR, 5-aza-CdR, zebularine, and RG108 caused concentration-dependent demethylation of genomic DNA.
• RG108 was found to be the only drug capable of direct enzyme inhibition in a cell-free in vitro assay with purified recombinant DNA methyltransferase.
• The study provides valuable insights into the developmental potential of individual drugs and has the potential to revolutionize cancer treatment.

Statistics:

• 6 DNA methyltransferase inhibitors were tested in the study: 5-azacytidine (5-aza-CR), 5-aza-2'-deoxycytidine (5-aza-CdR), zebularine, procaine, (-)-epigallocatechin-3-gallate (EGCG), and RG108.
• 4 of the 6 inhibitors (5-aza-CR, 5-aza-CdR, zebularine, and EGCG) were found to exhibit significant cytotoxicity in human cancer cell lines.
• 2 of the 6 inhibitors (5-aza-CdR and EGCG) were found to be genotoxic.
• 4 of the 6 inhibitors (5-aza-CR, 5-aza-CdR, zebularine, and RG108) caused concentration-dependent demethylation of genomic DNA.
• 1 of the 6 inhibitors (RG108) was found to be the only drug capable of direct enzyme inhibition.

Sources:

• C. Stresemann et al., "Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines." Cancer Res, 2006;66(5):2794-2800.
• F. Lyko, Deutsch Krebsforschungszentrum, Division of Epigenetics, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.
• American Association of Cancer Research, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404, USA.